The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applications HUNTSVILLE, Ala., Oct. 27, 2026 (GLOBE NEWSWIRE) — Gannet BioChem, a specialized contract development and manufacturing organization (CDMO) focused on activated polymers and bioconjugation, and Re-Vana…
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults…
In a sitting room in Surulere in the second week of October 2026, a twenty-six-year-old with a first degree in microbiology read the same email four times before she called her mother in from the…
